

SHARMA EAST INDIA HOSPITALS AND MEDICAL RESEARCH LTD.  
Registered office: JAIPUR HOSPITAL, LAL KOTHI, NEAR SMS STADIUM, TONK  
ROAD, JAIPUR - 302015 (Rajasthan)  
CIN: L85110RJ1989PLC005206

15/09/2020

To,  
The Manager,  
Corporate Relationship Department,  
BSE Ltd.  
25th Floor, P.J. Towers,  
Dalal Street, Fort,  
MUMBAI-400 001.

**Ref: Scrip Code: - 524548**

**Sub:** - Outcome of Board Meeting held on 15<sup>th</sup> September, 2020 pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Regulations").

Dear Sir/Ma'am,


The Board of Directors of the Company in their meeting held on 15<sup>th</sup> September, 2020 at the registered office of the Company situated at Jaipur Hospital, Near SMS Stadium, Lal Kothi, Tonk Road, Jaipur at 04:00 P.M. to 05.45 P.M. inter alia transacted the following business:

1. Approved the Unaudited Financial Results of the Company in compliance with Regulation 33 and Took on record the Limited Review Report for the period ended on 30<sup>th</sup> June, 2020 (Copy Enclosed)
2. The Board took note of various Compliances for the Quarter ended on 30<sup>th</sup> June, 2020 pertinent to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take it on record and acknowledge the same.

Thanking You,

For SHARMA EAST INDIA HOSPITALS &  
MEDICAL RESEARCH LTD.

  
Shailendra Kumar Sharma  
(Managing Director)



Contact: 0141-2742266 / 2742619  
Fax: 0141-2742472

E-mail - sharmaeastindia@gmail.com  
Website: www.jaipurhospital.co.in

SHARMA EAST INDIA HOSPITALS AND MEDICAL RESEARCH LTD.  
Registered office: JAIPUR HOSPITAL, LAL KOTHI, NEAR SMS STADIUM, TONK ROAD, JAIPUR  
- 302015 (Rajasthan)  
CIN: L85110RJ1989PLC005206

15.09.2020

To,  
The Manager,  
Corporate Relationship Department,  
BSE Ltd.  
25th Floor P.J. Towers,  
Dalal Street, Fort,  
MUMBAI-400 001.

**Ref: Scrip Code: - 524548**

**Sub: - Submission of Standalone Unaudited Financial Results for the quarter ended 30.06.2020 under regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir,

Please find enclosed herewith the Standalone Unaudited Financial Results for the quarter ended 30.06.2020 in compliance of regulation 30 read with 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 duly approved by the Board of Directors of the Company in their meeting held on Tuesday, 15<sup>th</sup> September, 2020 alongwith Auditor's Report on Limited Review.


Kindly take it on record and acknowledge the same.

Thanking You,

For **SHARMA EAST INDIA HOSPITALS &  
MEDICAL RESEARCH LIMITED**



**SHAIENDRA KUMAR SHARMA**  
(Managing Director)



Contact: 0141-2742266 / 2742619  
Fax: 0141-2742472

E-mail - sharmaeastindia@gmail.com  
Website: www.jaipurhospital.co.in

**SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED**  
NEAR SMS STADIUM, LAL KOTHI, TONK ROAD  
JAIPUR

CIN: L85110RJ1989PLC005206

**Statement of Standalone Unaudited Financial Results for the Quarter Ended 30th June, 2020**

(Rs. in lakhs)


S. No.	Particulars	Quarter Ended			Year Ended
		30.06.2020 (Unaudited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)
<b>1</b>	<b>Income from Operations</b>				
(a)	Revenue from Operations	101.88	393.49	432.92	1,616.73
(b)	Other Income	-	(3.19)	6.50	3.31
	<b>Total Revenue</b>	<b>101.88</b>	<b>390.30</b>	<b>439.42</b>	<b>1,620.04</b>
<b>2</b>	<b>Expenses</b>				
(a)	Cost of materials consumed	5.46	39.38	57.56	195.14
(b)	Purchase of stock in trade	0.02	1.17	1.84	4.65
(c)	Change in Inventories of stock in trade	-	(0.40)	(0.10)	(0.25)
(d)	Employee benefits expense	36.76	83.63	68.58	305.91
(e)	Finance cost	20.93	38.61	41.56	115.39
(f)	Depreciation and amortisation expense	8.56	10.14	10.88	42.86
(g)	Other Expenses	67.92	198.68	249.80	918.63
	<b>Total Expenses</b>	<b>139.65</b>	<b>371.21</b>	<b>430.12</b>	<b>1,582.33</b>
<b>3</b>	<b>Profit/(Loss) before exceptional items &amp; tax (1-2)</b>	<b>(37.77)</b>	<b>19.09</b>	<b>9.30</b>	<b>37.71</b>
<b>4</b>	<b>Exceptional Items</b>	-	-	-	-
<b>5</b>	<b>Profit/(Loss) before tax (3-4)</b>	<b>(37.77)</b>	<b>19.09</b>	<b>9.30</b>	<b>37.71</b>
<b>6</b>	<b>Tax expense</b>				
	Current tax	-	5.88	-	5.88
	Taxation for Earlier year	-	(0.03)	-	(0.03)
	Deferred tax	-	1.26	1.59	1.26
		-	7.11	1.59	7.11
<b>7</b>	<b>Profit/(Loss) for the period (5-6)</b>	<b>(37.77)</b>	<b>11.98</b>	<b>7.71</b>	<b>30.60</b>
<b>8</b>	<b>Other Comprehensive Income</b>				
(i)	Items that will not be reclassified to profit or loss	-	-	-	9.19
(ii)	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	(0.96)
	<b>Other Comprehensive Income for the period</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>8.23</b>
<b>9</b>	<b>Total Comprehensive Income (7+8)</b>	<b>(37.77)</b>	<b>11.98</b>	<b>7.71</b>	<b>38.83</b>
<b>10</b>	<b>Paid up equity share capital (face value of Rs. 10/- each)</b>	<b>328.38</b>	<b>328.38</b>	<b>328.38</b>	<b>328.38</b>
<b>11</b>	<b>Earning per share</b>				
	Basic	-	0.36	0.23	1.18
	Diluted	-	0.36	0.23	1.18

**Notes:**

- These results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 15.09.2020. Audit Report on the above financial results has been received from the Statutory Auditors of the Company.
- The figures of previous period/year have been re-grouped/re-arranged and / or recast wherever found necessary.
- The amounts for three months ended 31st March 2020 are balancing amounts between the amounts as per audited accounts for the year ended 31st March 2020 and nine months ended on 31st December 2019  
The Outbreak of COVID 19 pandemic and consequent lockdown has impacted the regular business operations. The results for the quarter are therefore not comparable with those for the previous quarter/ respective previous quarter. The Company has assessed the impact of pandemic on its financial results/ position based on the internal and external information available upto the date of approval of these financial results and expects that there will not be material change in the carrying value of its assets. The Company continues to monitor the economic effects of the pandemic while taking steps to improve its execution efficiencies and the financial outcome.

Place : Jaipur  
Date : 15.09.2020

For and on behalf of the Board of Directors Sharma East India Hospitals & Medical Research Limited





**Amit Goyal & Co.**  
CHARTERED ACCOUNTANTS

A-8, II Floor, Ganpati Enclave,  
Ajmer Road, JAIPUR - 302 006  
Tel.No. : 2225036, 2225065  
Fax : 0141-2223211

E-mail : amitgoyalnco@yahoo.com

Date: 15/09/2020

UDIN - 20075730AAAABV5942

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

The Board of Directors

Sharma East India Hospitals & Medical Research Limited

1. We have reviewed the accompanying statement of unaudited financial results of Sharma East India Hospitals & Medical Research Limited (the "company") for the quarter ended June 30, 2020 (the "Statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.


3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical



procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Amit Goyal & Co.  
Chartered Accountants  
ICAI Firm registration number: 003778C



Rajeev Kumar  
Partner

Membership No. 075730

UDIN: 20075730AAAABV5942

Place: Jaipur

Date: September 15, 2020